Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank73
3Y CAGR-8.8%
5Y CAGR+4.3%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-8.8%/yr
vs +19.1%/yr prior
5Y CAGR
+4.3%/yr
Recent deceleration
Acceleration
-28.0pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$40.10M-8.7%
2025$43.93M-24.1%
2024$57.85M+9.4%
2023$52.89M+16.3%
2022$45.48M+39.8%
2021$32.54M+18.9%
2020$27.36M+4.2%
2019$26.25M+12.0%
2018$23.44M+13.0%
2017$20.75M-